GlassScriptPhysician profile
Todd G Cohan
NPI 1841244878
$35,444.66
in general payments reported to CMS, 2019-2025
21 companies · $2,670 in 2025
The $2,670 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $266 · 2021: $643 · 2022: $4,102 · 2023: $9,329 · 2024: $2,445 · 2025: $2,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,290.87 |
| Food and Beverage | $3,153.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $19,232.50 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Johnson & Johnson Surgical Vision, INC. | $13,226.60 | 2021-2025 | Lipiflow System Activator (Disposable), Amo Phaco Needle |
| Bausch & Lomb Americas INC. | $568.80 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Coopervision INC. | $482.39 | 2022-2025 | Myday Contact Lens, Paragon Crt |
| Novartis Pharmaceuticals Corporation | $335.20 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $301.13 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.16 | 2019-2021 | |
| Lumenis Be INC | $197.13 | 2025 | Optilight |
| Allergan, INC. | $184.92 | 2020-2022 | |
| Abbvie INC. | $148.16 | 2022-2023 | Vuity, Lumigan |
| Tarsus Pharmaceuticals, INC. | $118.73 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $116.01 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $56.33 | 2021-2024 | |
| Biotissue Holdings INC. | $55.22 | 2019-2021 | |
| Shire North American Group INC | $48.62 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus, INC. | $44.01 | 2019 | |
| Harrow Eye, LLC | $34.92 | 2025 | Vevye |
| Dompe US, INC. | $20.05 | 2025 | Oxervate |
| Sight Sciences, INC. | $18.62 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Oyster Point Pharma, INC. | $14.92 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Cohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.